Characterizing Pharmacogenetic Testing Among Children’s Hospitals
Although pharmacogenetic testing is becoming increasingly common across medical subspecialties, a broad range of utilization and implementation exists across pediatric centers. Large pediatric institutions that routinely use pharmacogenetics in their patient care have published their practices and e...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-03-01
|
Series: | Clinical and Translational Science |
Online Access: | https://doi.org/10.1111/cts.12931 |
id |
doaj-c8b2cc9e26bc49a8bd6ad877ef14041e |
---|---|
record_format |
Article |
spelling |
doaj-c8b2cc9e26bc49a8bd6ad877ef14041e2021-03-25T15:37:46ZengWileyClinical and Translational Science1752-80541752-80622021-03-0114269270110.1111/cts.12931Characterizing Pharmacogenetic Testing Among Children’s HospitalsJacob T. Brown0Laura B. Ramsey1Sara L. Van Driest2Ida Aka3Susan I. Colace4Department of Pharmacy Practice and Pharmaceutical Sciences College of Pharmacy University of Minnesota Duluth Duluth Minnesota USADepartment of Pediatrics University of Cincinnati College of Medicine Cincinnati Ohio USADepartment of Pediatrics Vanderbilt University Medical Center Nashville Tennessee USADepartment of Pediatrics Vanderbilt University Medical Center Nashville Tennessee USADepartment of Pediatrics Nationwide Children’s Hospital Columbus Ohio USAAlthough pharmacogenetic testing is becoming increasingly common across medical subspecialties, a broad range of utilization and implementation exists across pediatric centers. Large pediatric institutions that routinely use pharmacogenetics in their patient care have published their practices and experiences; however, minimal data exist regarding the full spectrum of pharmacogenetic implementation among children’s hospitals. The primary objective of this nationwide survey was to characterize the availability, concerns, and barriers to pharmacogenetic testing in children’s hospitals in the Children’s Hospital Association. Initial responses identifying a contact person were received from 18 institutions. Of those 18 institutions, 14 responses (11 complete and 3 partial) to a more detailed survey regarding pharmacogenetic practices were received. The majority of respondents were from urban institutions (72%) and held a Doctor of Pharmacy degree (67%). Among all respondents, the three primary barriers to implementing pharmacogenetic testing identified were test reimbursement, test cost, and money. Conversely, the three least concerning barriers were potential for genetic discrimination, sharing results with family members, and availability of tests in certified laboratories. Low‐use sites rated several barriers significantly higher than the high‐use sites, including knowledge of pharmacogenetics (P = 0.03), pharmacogenetic interpretations (P = 0.04), and pharmacogenetic‐based changes to therapy (P = 0.03). In spite of decreasing costs of pharmacogenetic testing, financial barriers are one of the main barriers perceived by pediatric institutions attempting clinical implementation. Low‐use sites may also benefit from education/outreach in order to reduce perceived barriers to implementation.https://doi.org/10.1111/cts.12931 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jacob T. Brown Laura B. Ramsey Sara L. Van Driest Ida Aka Susan I. Colace |
spellingShingle |
Jacob T. Brown Laura B. Ramsey Sara L. Van Driest Ida Aka Susan I. Colace Characterizing Pharmacogenetic Testing Among Children’s Hospitals Clinical and Translational Science |
author_facet |
Jacob T. Brown Laura B. Ramsey Sara L. Van Driest Ida Aka Susan I. Colace |
author_sort |
Jacob T. Brown |
title |
Characterizing Pharmacogenetic Testing Among Children’s Hospitals |
title_short |
Characterizing Pharmacogenetic Testing Among Children’s Hospitals |
title_full |
Characterizing Pharmacogenetic Testing Among Children’s Hospitals |
title_fullStr |
Characterizing Pharmacogenetic Testing Among Children’s Hospitals |
title_full_unstemmed |
Characterizing Pharmacogenetic Testing Among Children’s Hospitals |
title_sort |
characterizing pharmacogenetic testing among children’s hospitals |
publisher |
Wiley |
series |
Clinical and Translational Science |
issn |
1752-8054 1752-8062 |
publishDate |
2021-03-01 |
description |
Although pharmacogenetic testing is becoming increasingly common across medical subspecialties, a broad range of utilization and implementation exists across pediatric centers. Large pediatric institutions that routinely use pharmacogenetics in their patient care have published their practices and experiences; however, minimal data exist regarding the full spectrum of pharmacogenetic implementation among children’s hospitals. The primary objective of this nationwide survey was to characterize the availability, concerns, and barriers to pharmacogenetic testing in children’s hospitals in the Children’s Hospital Association. Initial responses identifying a contact person were received from 18 institutions. Of those 18 institutions, 14 responses (11 complete and 3 partial) to a more detailed survey regarding pharmacogenetic practices were received. The majority of respondents were from urban institutions (72%) and held a Doctor of Pharmacy degree (67%). Among all respondents, the three primary barriers to implementing pharmacogenetic testing identified were test reimbursement, test cost, and money. Conversely, the three least concerning barriers were potential for genetic discrimination, sharing results with family members, and availability of tests in certified laboratories. Low‐use sites rated several barriers significantly higher than the high‐use sites, including knowledge of pharmacogenetics (P = 0.03), pharmacogenetic interpretations (P = 0.04), and pharmacogenetic‐based changes to therapy (P = 0.03). In spite of decreasing costs of pharmacogenetic testing, financial barriers are one of the main barriers perceived by pediatric institutions attempting clinical implementation. Low‐use sites may also benefit from education/outreach in order to reduce perceived barriers to implementation. |
url |
https://doi.org/10.1111/cts.12931 |
work_keys_str_mv |
AT jacobtbrown characterizingpharmacogenetictestingamongchildrenshospitals AT laurabramsey characterizingpharmacogenetictestingamongchildrenshospitals AT saralvandriest characterizingpharmacogenetictestingamongchildrenshospitals AT idaaka characterizingpharmacogenetictestingamongchildrenshospitals AT susanicolace characterizingpharmacogenetictestingamongchildrenshospitals |
_version_ |
1724203454430183424 |